Ramsey L, Balis F, OBrien M, Schmiegelow K, Pauley J, Bleyer A
Oncologist. 2017; 23(1):52-61.
PMID: 29079637
PMC: 5759822.
DOI: 10.1634/theoncologist.2017-0243.
Gangjee A, Jain H, Phan J, Lin X, Song X, McGuire J
J Med Chem. 2006; 49(3):1055-65.
PMID: 16451071
PMC: 2547132.
DOI: 10.1021/jm058276a.
Schalhorn A, Siegert W, Sauer H
Eur J Clin Pharmacol. 1981; 20(3):219-24.
PMID: 7286039
DOI: 10.1007/BF00544601.
Howell S, Chu B, Wung W, Metha B, Mendelsohn J
J Clin Invest. 1981; 67(4):1161-70.
PMID: 6970753
PMC: 370677.
DOI: 10.1172/jci110130.
Tracey K, Mutkoski R, Lopez J, Franzblau W, Franzblau C
Cancer Chemother Pharmacol. 1983; 10(2):96-9.
PMID: 6831631
DOI: 10.1007/BF00446217.
Methotrexate and methotrexate polyglutamates in human sarcoma metastases after high-dose methotrexate therapy.
Schalhorn A, Sauer H, Wilmanns W
Klin Wochenschr. 1983; 61(21):1089-94.
PMID: 6196516
DOI: 10.1007/BF01496470.
Comparison of leucovorin protection from variety of antifolates in human lymphoid cell lines.
Browman G, SPIEGL P, Booker L, Rosowsky A
Cancer Chemother Pharmacol. 1985; 15(2):111-4.
PMID: 3874720
DOI: 10.1007/BF00257519.
Pharmacokinetics of anticancer drugs in children.
Crom W, Rodman J, Teresi M, Kavanagh R, Christensen M, Relling M
Clin Pharmacokinet. 1987; 12(3):168-213.
PMID: 3555940
DOI: 10.2165/00003088-198712030-00002.
The influence of high-dose methotrexate therapy on serum iron.
Schalhorn A, Wilmanns W, Koczorek G
Klin Wochenschr. 1986; 64(10):475-80.
PMID: 3459938
DOI: 10.1007/BF01713173.
Differential calcium leucovorin protection of human lymphoid cell lines from methotrexate.
Browman G, Booker L, SPIEGL P
Cancer Chemother Pharmacol. 1985; 15(2):105-10.
PMID: 2410158
DOI: 10.1007/BF00257518.
The practical use of methotrexate in psoriasis.
Tung J, Maibach H
Drugs. 1990; 40(5):697-712.
PMID: 2292232
DOI: 10.2165/00003495-199040050-00005.
Rapid chemosensitivity assay with human normal and tumor cells in vitro.
Borenfreund E, Babich H, Martin-Alguacil N
In Vitro Cell Dev Biol. 1990; 26(11):1030-4.
PMID: 2177465
DOI: 10.1007/BF02624436.
Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy.
Lee J, Murphy W, Shirinian M, Pang A, Hong W
Cancer Chemother Pharmacol. 1991; 28(3):199-204.
PMID: 1649705
DOI: 10.1007/BF00685509.
High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach.
Monjanel S, Rigault J, Cano J, Carcassonne Y, Favre R
Cancer Chemother Pharmacol. 1979; 3(3):189-96.
PMID: 527209
DOI: 10.1007/BF00262421.
High-dose methotrexate with citrovorum factor rescue in non-small-cell lung cancer.
Greco F, Fer M, Richardson R, Hande K, van Boxtel C, Oldham R
Cancer Chemother Pharmacol. 1978; 1(4):255-7.
PMID: 373922
DOI: 10.1007/BF00257159.
Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.
Evans W, Pratt C, Taylor R, Barker L, Crom W
Cancer Chemother Pharmacol. 1979; 3(3):161-6.
PMID: 316744
DOI: 10.1007/BF00262416.
[High-dose methotrexate therapy in osteogenic sarcoma: plasma pharmakokinetics to predict toxicity (author's transl)].
Janka G, Wiesner H, Bidlingmaier F, Haas R
Klin Wochenschr. 1979; 57(8):411-6.
PMID: 313478
DOI: 10.1007/BF01480480.
